Reziciclideg
Reziciclideg is an orally active, potent dual CDK4 and CDK6 degrader with DC50 values ≤ 5 nM for both. Reziciclideg potently induces intracellular degradation of CDK4 and CDK6 proteins, blocks downstream RB protein phosphorylation (pRB Ser807/811), and inhibits the G1-to-S phase transition of the cell cycle, thereby suppressing tumor cell proliferation and overcoming CDK4/6 inhibitor resistance. Reziciclideg can be used for research on breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 3011828-23-9
- Formula: C42H51N9O4
- Molecular Weight:745.91
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
CDK4 ≤ 5 nM (DC50) |
CDK6 ≤ 5 nM (DC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| T47D | IC50 |
≤ 10 nM
|
Potently inhibits tumor activity.
Potently inhibits tumor activity.
|
WO2025264885A2 |
| ZR-75-1 | IC50 |
≤ 10 nM
|
Potently inhibits tumor activity.
Potently inhibits tumor activity.
|
WO2025264885A2 |
In Vitro
Reziciclideg (0.76 nM-5 μM; 10 days) potently inhibits the cell proliferation of T47D (IC50 ≤ 10 nM), ZR751 (IC50 ≤ 10 nM), MCF-7 (10 nM < IC50 ≤ 50 nM), and MDA-MB-231 (10 nM < IC50 ≤ 50 nM)[2].
Reziciclideg (1.52 nM-10 μM; 24 h) potently inhibits the phosphorylation level of RB (Ser807/811) in MDA-MB-231 (IC50 ≤ 10 nM) and MCF-7 (10 nM < IC50 ≤ 50 nM)[2].
Reziciclideg (compound B227) (0.1-1 μM; 6 h) potently degrades CDK4 (degradation rate ≥ 50% at both 0.1 μM and 1 μM) and CDK6 (degradation rate ≥ 50% at both 0.1 μM and 1 μM) in MDA-MB-231 cells, while exhibiting only low to moderate degradation of CDK2 (degradation rate 10%-25% at 0.1 μM and 25%-50% at 1 μM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human triple-negative breast cancer MDA-MB-231 cells
-
Concentration:10 nM, 100 nM, and 1 μM
-
Incubation Time:6 h
-
Result:Potently degraded both CDK4 and CDK6 in MDA-MB-231 cells, achieving ≥50% degradation (Grade A) at both 0.1 and 1 μM, with DC50 ≤ 5 nM (Grade A) and Dmax ≥ 80% (Grade A) for both CDK4 and CDK6; in contrast, CDK2 degradation was 10%-25% (Grade C) at 0.1 μM and 25%-50% (Grade B) at 1 μM.
-
Cell Line:Human ER+/HER2- breast cancer MCF-7 (500 cells/well), T47D (600 cells/well), and ZR751 (1,000 cells/well) cells; human TNBC MDA-MB-231 (150 cells/well) cells
-
Concentration:9 concentrations starting at 5 μM with 1:3 serial dilution down to 0.76 nM (5000, 1666.67, 555.56, 185.19, 61.73, 20.58, 6.86, 2.29, and 0.76 nM)
-
Incubation Time:10 days
-
Result:Inhibited the proliferation of all four breast cancer cell lines, with IC50 ≤ 10 nM (Grade A) in T47D and ZR751 cells and 10 nM < IC50 ≤ 50 nM (Grade B) in MCF-7 and MDA-MB-231 cells.
-
Cell Line:ER+/HER2- breast cancer MCF-7 and TNBC MDA-MB-231
-
Concentration:9 concentrations starting at 10 μM with 1:3 serial dilution down to 1.52 nM (10000, 3333.33, 1111.11, 370.37, 123.46, 41.15, 13.72, 4.57, and 1.52 nM)
-
Incubation Time:24 h
-
Result:Potently suppressed RB Ser807/811 phosphorylation with an IC50 ≤ 10 nM (Grade A) in MDA-MB-231 cells and 10 nM < IC50 ≤ 50 nM (Grade B) in MCF-7 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude mice (female)[2]
-
Dosage:50 mg/kg
-
Administration:p.o.; once daily; 28 days
-
Result:Achieved 3.4% tumor regression on Day 28 in the MCF-7 xenograft model, outperforming the approved CDK4/6 inhibitors.
- Western Blot
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- Protocol for Cell Cycle
- CCK-8/WST-8 Cell Proliferation Assay
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Breast Cancer Modeling
- Cell Viability Determination by MTT Colorimetric Assay
- Kinase activity and phosphorylation assays
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- Flow cytometric DNA-content cell-cycle staining
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- Protocol for Kinase activity and phosphorylation assays
- MTT Cell Proliferation Assay
Chemical Information
-
CAS No. 3011828-23-9
-
Molecular Weight 745.91
-
Formula C42H51N9O4
-
SMILES
O=C1C(C(C)=O)=C(C)C2=C(N1C3CCCC3)N=C(NC4=NC=C(N5CCC(CCN6CCN(CC6)C7=CC=C(C8C(NC(CC8)=O)=O)C=C7)CC5)C=C4)N=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)